CLIA: 39D2085645
New York State has a separate and unique regulatory approval process for laboratory diagnostic testing. PeriRx is currently in the application process with our SaliMark™ OSCC test and is vigorously committed to pursuing this application approval.
Fall in PSA Screening Resulting in More Advanced Disease
Studies looking at the consequences of American recommendations against routine screening for prostate cancer with the prostate-specific antigen (PSA) have already had an impact on older men, who are now diagnosed with more advanced prostate cancers. The same is being predicted for younger men. Findings from two studies were presented here at the European Association of Urology 2016 Congress. [Read more…]